Abstract:Abstract BackgroundIt is now 25 years since the adoption of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the same concerns raised during its negotiations such as high prices of medical products, market exclusivity and delayed market entry for generics remain relevant as highlighted recently by Ebola and COVID-19 pandemics. The World Health Organization’s mandate to work on the interface between intellectual property, innovation and access to medicine has been continually reinforced and extended to include providing support to countries on the implementation of TRIPS flexibilities in collaboration with stakeholders. This study analyses the role of intellectual property on innovation and access to medical products in the African Region. Methods:We analyze patent data from the African Regional Intellectual Property Organization (ARIPO) and Organisation Africaine de la Propriété Intellectuelle (OAPI) to show trends and to identify the main diseases covered and how they correspond with top causes of morbidity and mortality. We also review legislation to assess how TRIPS flexibilities are implemented in countries.ResultsPatenting was low for African countries. Only South Africa and Cameroon appeared in the list of top ten originator countries for ARIPO and OAPI respectively. Main diseases covered by African patents were HIV/AIDS, cardiovascular diseases, cancers and tumors. 39 countries have applied TRIPS flexibilities, with the most common being compulsory licensing and LDC transition provisions. A third of the compulsory licensing application were not executed following voluntary licensing agreements. No country had legislated on research and regulatory review exceptions and patent term extension.DiscussionThere’s modest alignment between innovation and health challenges. Compulsory licensing applications may have served to encourage voluntary licensing arrangements. Countries have enacted laws that allow them to deploy TRIPS flexibilities for public health needs. ConclusionsThere’s need to develop and strengthen health innovation systems in the region. Opportunities exist for WHO to work with ARIPO and OAPI to support countries in reviewing their legislation to be more responsive to public health needs.

TRIPS Agreement and Public Health

TRIPS and the Primacy of Public Health

Balance of Interests and Humanitarian Concerns

WTO and Global Public Health Governance:A Case Study of TRIPS

The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property

The COVID-19 Pandemic and the TRIPS Waiver: Patents and Flexibility

Reconciling the global public health interest with intellectual property protection through the waiver of certain provisions of the WTO TRIPS Agreement

TRIPS-plus and Access to Medicines in China.

Patents, trade and medicines: past, present and future

TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

TRIPS and Developing Countries

The Trans-Pacific Partnership and pharmaceutical innovation

Protection of intellectual property and human rights during health emergencies: an assessment of the patent waiver proposal

Intellectual Property, COVID-19 Vaccines and Equity: A Public Health and Human Rights Critique

Temporary Waiver of Patent Rights in Public Health Emergencies: Inadequacy of Provisions during the COVID-19 Crisis

COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform

Intellectual Property as a Determinant of Health

Exploiting treaty ambiguity: Public health exceptions in the WTO TRIPS agreement

Global Health Jurisprudence: COVID-19 Pandemic and Pharmaceutical Patents

From TRIPS to FTAs and Back: Re-Conceptualising the Role of a Multilateral IP Framework in a TRIPS-Plus World

The Role of Intellectual Property Rights and Access to Medical Products in the WHO African Region: 25 Years After the Trips Agreement